XML 23 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 30,699 $ 39,067
Short-term investments 245,737 197,959
Accounts receivable, net 3,047 2,229
Inventory 14,111 13,452
Other current assets 4,629 5,175
Total current assets 298,223 257,882
Restricted cash 25,000 25,000
Property and equipment, net 71,070 66,974
Goodwill 76,501 76,501
Other assets 7,343 8,170
Total assets 478,137 434,527
Current liabilities:    
Accounts payable 7,437 9,115
Accrued compensation 11,386 14,254
Accrued expenses 5,814 6,243
Accrued clinical trial expenses 13,208 16,905
Interest payable 6,917 6,917
Deferred revenue, current portion 24,766 23,664
Other current liabilities 14,827 21,123
Total current liabilities 84,355 98,221
Senior secured notes 125,000 125,000
Capital lease obligations, less current portion 6,025 8,049
Liability related to receipt of refundable milestone payment 70,000 70,000
Liability related to sale of future royalties, less current portion 121,431 121,520
Deferred revenue, less current portion 88,918 82,384
Other long-term liabilities 17,768 19,256
Total liabilities 513,497 524,430
Commitments and contingencies      
Stockholders' equity (deficit):    
Preferred stock, $0.0001 par value; 10,000 shares authorized, no shares designated, issued or outstanding at June 30, 2014 or December 31, 2013, respectively 0 0
Common stock, $0.0001 par value; 300,000 authorized; 127,286 shares and 116,494 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively 12 11
Capital in excess of par value 1,776,746 1,643,660
Accumulated other comprehensive loss (887) (1,181)
Accumulated deficit (1,811,231) (1,732,393)
Total stockholders' equity (deficit) (35,360) (89,903)
Total liabilities and stockholders' equity (deficit) $ 478,137 $ 434,527